GENEURO SA (EPA:GNRO) | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
GENEURO SA

PRESS RELEASE

published on 06/14/2024 at 18:30, 5 months 6 days ago

Informations privilégiées / Autres communiqués
Les actionnaires de GeNeuro approuvent l’ensemble des résolutions proposées à l’Assemblée Générale Annuelle 2024. 81,54% du capital social de la société était représenté à l'assemblée générale et les résolutions ont toutes été approuvées à l’unanimité

Actionnaires Resolutions Assemblée Générale Annuelle Approbation GeNeuro
BRIEF

published on 05/29/2024 at 19:32, 5 months 22 days ago

GeNeuro: Information on the General Meeting of June 12, 2024

Shareholders Biopharmaceutical Multiple Sclerosis General Assembly GeNeuro
BRIEF

published on 05/29/2024 at 19:32, 5 months 22 days ago

GeNeuro : Informations sur l'Assemblée Générale du 12 juin 2024

Actionnaires Assemblée Générale Biopharmaceutique Sclérose En Plaques GeNeuro
PRESS RELEASE

published on 05/29/2024 at 19:27, 5 months 22 days ago

Inside Information / Other news releases
GeNeuro announces availability of documents for the annual shareholders’ meeting on June 12, 2024 in Geneva, Switzerland. Documents accessible online and at company headquarters

Shareholders' Meeting Annual Meeting GeNeuro Geneva Documents Availability
PRESS RELEASE

published on 05/29/2024 at 19:27, 5 months 22 days ago

Informations privilégiées / Autres communiqués
GeNeuro annonce les modalités de mise à disposition des informations pour son assemblée générale des actionnaires du 12 juin 2024. Consultation en ligne ou au siège social à Genève

Actionnaires Assemblée Générale Modalités GeNeuro Genève
BRIEF

published on 04/30/2024 at 19:59, 6 months 20 days ago

GeNeuro présente ses résultats annuels 2023 et progresse dans ses programmes de recherche

Résultats Financiers Santé Recherche Médicale GeNeuro SA COVID Long
BRIEF

published on 04/30/2024 at 19:59, 6 months 20 days ago

GeNeuro presents its 2023 annual results and progresses in its research programs

Financial Results Long Covid Medical Research Health GeNeuro SA
PRESS RELEASE

published on 04/30/2024 at 19:54, 6 months 20 days ago

Inside Information / News release on accounts, results
GeNeuro reports 2023 full-year results and provides corporate update including completion of Phase 2 trial for temelimab against post-COVID neuropsychiatric syndromes. Financial visibility extended to Q3 2024

Full-year Results Phase 2 Trial GeNeuro Temelimab Post-COVID
PRESS RELEASE

published on 04/30/2024 at 19:54, 6 months 20 days ago

Informations privilégiées / Communiqué sur comptes, résultats
GeNeuro annonce ses résultats annuels 2023 et fait le point sur ses développements. Essai clinique de phase 2 avec temelimab dans les syndromes neuropsychiatriques Post-COVID. Position de trésorerie de 2,8 millions d'euros au 31 décembre 2023

Résultats Annuels GeNeuro Temelimab Syndromes Neuropsychiatriques Post-COVID

Accesswire

Published on 11/21/2024 at 12:00, 1 hour 8 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 1 hour 8 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 38 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 3 hours 5 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 3 hours 8 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 33 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 53 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 2 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 8 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 38 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 10 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 10 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 10 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 1 minute ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 48 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE